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ABSTRACT
Tumor-related cerebral edema is a debilitating medical condition that afflicts tens of thousands
of newly diagnosed brain cancer patients in the U.S. each year, where the standard care of
treatment indicates the systemic administration of dexamethasone sodium phosphate (DXM) and
surgery. The former is associated with toxic side effects, and the latter is an ineffective option.
Local drug delivery to the desired site of therapy helps to circumvent the side effects of DXM.
In this paper, the design of a novel, local drug delivery device was explored as a means to treat
tumor-related cerebral edema. The novel device was then evaluated based on an analysis of the
market environment in which it will be sold. This included discussion of the supply chain
infrastructure and the challenges associated with the medical industry, an estimate of the
addressable market size, growth and valuation, and an estimate of the novel product's cost
compared to current edema treatment and the device's potential competitors. The methods by
which the device could be commercialized were also discussed, specifically, strategies for
obtaining FDA approval, manufacturing the device on a medium scale, protecting intellectual
property, integrating the device into the supply chain, and an estimation of the financial
investment needed to form a startup company. Finally, the technology that enables its desired
application was evaluated, which included an assessment of the barriers to drug delivery, ideal
characteristics of a successful drug delivery device, possible routes and means of administration,
as well as other considerations pertinent to a successful drug delivery device. After completing
the first iteration of the innovation cycle, it was concluded that the device deserves further
investigation and investment, as it progresses from the lab bench to the marketplace.
Thesis Supervisor: Michael J. Cima, Ph.D.
Title: Sumitomo Electric Industries Professor of Engineering
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1 Introduction
1.1 Overview of Cerebral Edema
The volume of a human skull is fixed and is comprised of three basic components: brain tissue,
blood, and cerebrospinal fluid (CSF). According to the Monro-Kellie doctrine, a change in any
one of the basic intracranial volume constituents will in turn increase intracranial pressure (ICP)
. This is expressed by the linear equation below.
Vskuli - VBrain Tissue + VBiood + VCSF
However, there are several downstream cell mechanisms that help to auto-regulate normal ICP
levels. Typically measured from the foramen of Monro (i.e. intraventricular foramen), as shown
in Figure 1, the range of normal ICP levels is between 5 and 15 mm Hg. One particularly
important regulator of ICP is the blood-brain barrier (BBB), which controls the permeability of
different sized cells and molecules between the blood and brain tissue. The base membrane of a
brain's capillaries, as shown in the top illustration of Figure 2, is comprised of endothelial cells,
whose tight junctions are held together by cell adhesion molecules, such as astrocytes 2.
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Figure 1: Illustration of Sagittal View of Human Mid Brain3
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Figure 2: Cross-Section of Brain Capillary (top) and Illustration of Normal and Disrupted Blood-Brain Barriers
(bottom)4
Approximately 98% of small molecules (molecular weight > 500 Daltons or g/mol) and nearly
all macromolecules (molecular weight > 1 kD) are unable to cross a normal or healthy BBB 2
Molecules with high lipophilicity also "correlate strongly with cerebrovascular permeability"5.
These barriers, along with others, explain the challenge in treating CNS disorders using
pharmaceutical drugs, which have high molecular weight and are hydrophobic. However, the
normal function of the BBB can be disrupted by the onset of disease, thereby disrupting its
permeability. One cause of this disruption will be explored, specifically glial tumors or glioma.
Glioma is a cancer of the brain's glial tissue (comprised of astrocytes, oligodendrocytes, and
ependymal cells) that can increase ICP in two ways. Either the tumor mass itself increases the
volume of brain tissue, thereby leading to an increase in ICP, or the BBB of the tumor and
peritumoral sites are disrupted, thereby causing cerebral edema. Cerebral edema can be simply
understood as a "swelling" of the cranium's contents, which is more accurately described as a
sustained increase in ICP due to an excess amount of interstitial fluid that accumulates within the
extracellular spaces of the brain's tissue. The clinical symptoms associated with increased ICP
have been argued to be associated with -"the surrounding edema than by the tumor mass itself' 6,
which justifies the importance and urgency in treating cerebral edema.
In and around the tumor site, angiogenesis or the formation of new microvessels occurs, which
have a defective BBB. This abnormal permeability of the BBB allows plasma exudate to
contribute to the extracellular fluid volume between the brain's tissue7 . The three possible
mechanisms by which edema is regulated are "migration of extracellular water to the CSF by
bulk flow in the presence of [intratumoral] pressure gradients, glial uptake of the protein
components of edema fluid, and reverse vesicular transport from the blood via [the]
transendothelial passage"8. However, resorption is limited in many parts of the brain, where for
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example, the resorption rate of extravasated fluid is independent of ICP in the subarachnoid
space of the cranium 7 . Interstitial fluid will therefore accumulate to the extent that it
overwhelms the brain's natural "sink effect" that attempts to self-regulate ICP levels9, and as a
result this increases local pressure at the tumor site. This further results in an observable
increase in global ICP. The reason for concern about this increase in ICP is due to the
debilitating symptoms associated with its clinical incidence. Primary symptoms include focal
neurological deficits, such as loss of motor control and aphasia, and focal
electroencephalography (EEG) slowing. General clinical symptoms include disturbances of
consciousness, headache, nausea, vomiting, and drowsiness"6"0.
1.2 Treatment Options
In the U.S., the standard care of tumor-related cerebral edema is currently dominated by a
pharmacological approach. Below is a brief explanation and evaluation of each commercially
available drug.
Osmotherapy includes the use of drugs, such as mannitol, urea and glycerol, in order to create an
"osmotic gradient between brain and blood" 7. This is to reverse the flow of excess fluid back
into the blood. However, in the short term, a "rebound effect" occurs and only exacerbates the
original problem of increased permeability of the BBB, which means it is ineffective as a long-
term treatment".
Diuretics, such as furosemide, "cause systemic dehydration, which may increase the ventricular
sink effect"7. Although this may provide some immediate relief from the clinical symptoms
caused by edema, it does not address the root cause of its pathology. Therefore, this type of drug
provides an ineffective long-term treatment.
Dexamethasone sodium phosphate (DXM), a type of glucocorticoid steroid, is the most
commonly used. It is a preferred corticosteroid in the treatment of vasogenic edema because of
its low mineralocorticoid effects (i.e. minimal salt retention)". DXM is shown in many studies
to restore the normal permeability of the BBB "in part by causing dephosphorylation of the tightjunction component proteins occludin and ZO1"12, and by "reducing the expression of the
edema-producing factor [vascular endothelial growth factor] VEGF"". However, its long-term
use (i.e. > 2-3 weeks) can cause serious side effects, including "gastric ulceration or hemorrhage,
osteoporosis, Cushing's syndrome, and steroid myopathy" 7. A complete list of complications
can be found in the following reference 12 and its pharmacokinetics and pharmacodynamics can
be found in the following reference' 3
Surgery is also another part of the standard care of treatment for cerebral edema. Resection of
the brain tumor results in an effective removal of tissue with defective capillaries. However, this
is only an option for operable tumors. Patients with preoperative edema are also more likely to
develop post-operative edema as well, and the tumor can also recur, thereby recreating the
original problem. Therefore, this option is limited by its short-term effectiveness and the fact that
it cannot be done in every case.
Several pharmaceutical companies have attempted to develop new drugs in order to address the
ineffectiveness or the systemic toxicities associated with the previously discussed drugs. Some
of the most notable examples include, Argatroban (i.e. anti-thrombin agent), corticotropin-
releasing factor, anti-VEGF agents, and COX-2 inhibitors. A brief review of these drugs can be
found in the following references 9"14. These drugs, unfortunately, are either in their preclinical or
clinical phase of Food & Drug Administration (FDA) testing, where the likelihood of their
approval is slim and timeline for approval is long, due to the stringent and expensive FDA drug
approval process.
An alternate treatment option that will be considered in great detail in this paper is local drug
delivery to the brain. Using DXM, one could deliver the drug to the desired site it is needed.
There are several advantages to this method. Systemic toxic effects are circumvented, because
the majority of the drug payload is metabolized at the treatment site, and so even if the delivered
drug were to disperse into the bloodstream, it would have minimal toxic effect. A smaller drug
dosage would be required to have therapeutic effect, which would also reduce the likelihood of
systemic toxicity. And finally, the drug's distribution is more easily controlled and predictable.
1.3 Motivation, Scope & Objectives
Professor Michael J. Cima of the Department of Materials Science and Engineering has decided
to spearhead a project to address the problems associated with treating cerebral edema. He is
pursuing this project alongside other members of his laboratory research group - Convergence of
Medical Products - and other collaborators, such as oncologists and neurologists located in the
Boston area at Massachusetts General Hospital (MGH) and Brigham and Women's Hospital
(BWH).
Feedback from oncologists at MGH and BWH explained that patients diagnosed with glioma
described the symptoms associated with cerebral edema as "worse" or "more painful" than the
side-effects associated with chemotherapy and radiotherapy. Fishman further explains that only
in the short term does DXM outweigh the risks associated with its use6 .
According to an internet-based forum called the "Cancer Survivor Network" supported by the
American Cancer Society, patients also describe the morbidity and their quality of life associated
with DXM use. The majority of their side effects, in no particular order, include:
- Muscle atrophy of extremities,
- Addiction to DXM and "withdrawal syndrome",
- Psychological changes, such as psychosis and irritability,
- Weight gain,
- Double vision".
According to studies regarding the incidence of side effects due to DXM use, about 50% of
patients treated with DXM for at least 1 month develop glucose intolerance. At least 20% of all
patients who have been administered 8 mg per day for more than two weeks or those
administered an excess of that amount experience steroid myopathy - "subacute onset of wasting
and proximal muscle weakness" 2 . Most patients requiring DXM for longer than two weeks
experience "steroid withdrawal syndrome" or DXM addiction, which is "characterized by
arthralgias, myalgias, and joint pain, as well as.. .headache, depression, lethargy, and postural
dizziness" 0 . About 2% of all patients also contract a fungus-induced pneumonia, called
Pneumocystis. A more in-depth analysis of these incidence statistics can be found in the
following sources0 1 .
This project, at the time this paper was written, is still in its early stages. A preliminary design
for a drug delivery device has been devised, so the focus of the project is primarily focused on
the technology, rather than on market- and implementation-related aspects. The goal of this
paper, however, is to assess the potential success and feasibility of the proposed medical device
within a broader context. This context includes the three key elements to any innovation -
market, implementation and technology considerations.
1.4 Brief Overview of Proposed Solution
To treat a variety of brain-related diseases, such as
chronic meningitis and CNS neoplasms' 6,
repeated transcutaneous injections of drug into the
lateral ventricles are undesirable". Lumbar
punctures or spinal injections, as shown at the
bottom of Figure 3, which also serve to deliver
drugs to the CNS via CSF flow, are also
associated with decreased patient comfort and
increased stress and pain8 . A subcutaneously
implanted reservoir connected to a ventricular
catheter was invented, in response to this, to Carobm flu -
provide continuous drug delivery. The dome-
shaped reservoir is implanted in a burr-hole just
beneath the scalp, where it is filled with drug via
transcutaneous injection and used as a simple
pump to deliver drug to the lateral ventricles.
Since its introduction in 1963, an Ommaya
reservoir, named after its creator Dr. Ayub K.
Ommaya 17 has been in widespread use as a
means to circumvent the BBB and treat brain-
related disorders. The device is also referred to as
an "implantable reservoir," "ventricular access device" as well as other similar names.
Professor Michael Cima's basic idea is to utilize a modified version of an Ommaya reservoir to
locally deliver DXM over the long term, thereby significantly reducing the risk of systemic
toxicity. There are several proposals for how it should be specifically designed, such as what
materials it should be made of and how the drug should be prepared. A complete analysis and
evaluation of the technical considerations associated with this new device, including how it
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compares to other approaches and competing technologies for drug delivery to the brain, will
follow the discussion regarding market and implementation.
2 Market Analysis
2.1 Key Members of the U.S. Healthcare System
For any technology to become profitable in the marketplace, it is important to identify the
members of the supply chain and establish how their decisions to adopt this new technology are
influenced. The most relevant members of the U.S. supply chain include patients, hospitals or
physicians, healthcare insurance providers, manufacturers, and group purchasing organizations.
Patients, who are ultimately the innovation's end-user, are primarily concerned with obtaining
the best healthcare possible at an affordable price. This means the novel device should be priced
relative to the costs of current treatment, and will also depend upon healthcare insurance
reimbursement.
Hospitals or physicians want to provide the best clinical outcome and quality of life for their
patients. They can also serve as strong advocates for the novel device by soliciting patients.
This means that an effort needs to be made to introduce physicians to the innovation and prove
that it can provide a favorable clinical outcome.
Private health insurance providers, which contribute to 54% of the U.S.'s total healthcare
income 19, must also be convinced that the innovation is or has become a necessary part of
treatment. They are reluctant to cover the costs of new technologies, unless they exhibit a clearly
clinical advantage compared to the gold standard of treatment. The proposed device's ability to
treat cerebral edema without any toxic side effects is one of its primary clinical advantages. This
is a compelling argument that could convince insurance companies to cover, at least partially, the
innovation's expense. Public health insurance or Medicare, in contrast, "makes coverage
decisions based on a definition of 'reasonable and necessary' and does not explicitly integrate
cost in [its] deliberations"19. It will later be shown that more than half of all glioma patients are
over the age of 65 and therefore qualify for Medicare coverage. This means that healthcare
reimbursement will not pose a serious threat to the successful adoption of the new device in
clinical settings.
Medical device and pharmaceutical manufacturers, who would provide the initial channel needed
to deliver the innovation, aim to maximize their profits. They must be convinced that their
investment in this device will be outweighed by the profits gained from its sale'9 .
Group purchasing organizations (GPO), who serve as the "middle men" between manufacturers
and hospitals, aim to reduce the unit cost of medical products by negotiating bulk volume
purchases. These GPOs act as a barrier to the adoption of new medical innovations, "especially
for small and emerging technology companies"2 as it can reduce their total revenue stream,
thereby reducing their profit margins and incentive to introduce new innovations.
The introduction of a medical device into the marketplace that can safely and effectively provide
an improved clinical outcome is more likely to become adopted than other technologies, such as
consumer electronics. This is because a technology that improves a patient's health is more of a
priority to the consumer's overall well being than the release of, for example, a new videogame
console.
2.2 Medical Device Industry Challenges
Device recalls and device-related deaths are an ongoing concern. No matter how predictable the
device may prove to be, even after many clinical trials, the device could still fail and may result
in a loss of consumer confidence and market share. Another major barrier to the medical device
industry, from the perspective of small startup companies, is the monumental costs of research
and development, including "developing devices, conducting clinical trials, gaining FDA
approval and marketing devices"20 . This challenge is exacerbated by the ability of "well-
entrenched competitors" to more quickly and more easily, in terms of financial investment, bring
a new product to market. A startup can also be forced to dissolve as a result of the FDA's refusal
to approve the legal sale of the new device, or as a result of bankruptcy filing due to, for
example, litigation fees or a lawsuit with an unfavorable outcome.
2.3 Market Size, Growth & Valuation
Identifying the potential customer and quantifying the size, growth and valuation of that market
can help to justify its potential profitability.
In the U.S., it has been estimated that
more than 200,000 patients are
diagnosed with primary and
metastatic brain tumors each year21 .
Even though it is estimated by the
Central Brain Tumor Registry of the
United States (CBTRUS) that in
2010, 62,930 new cases of primary
brain cancer will be diagnosed in the
U.S.22. this number does not include
the number of brain tumors that
originate from other, more common
cancers (i.e. lung, breast,
melanoma)23 . It will be assumed that
the majority of the initially quoted
patients suffer from vasogenic edema
requiring treatment using DXM.
This means that a relatively large
market exists, but considering there
is no commercially available medical
device that directly treats cerebral
edema, an unmet market need exists
as well.
Age-Specific (Crude) SEER Incidence Rates
By Cancer Site
All Ages, All Races, Both Sexes
2000-2006
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Figure 4: Age Distribution of CNS Tumor Incidence in U.S.
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The incidence of brain and other CNS cancers also increase with age, as depicted in Figure 4. It
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shows the U.S. age-specific incidence rate for CNS tumors per 100,000 people . It is predicted
that by 2020 the U.S. population over the age of 65 will increase by approximately 50%18. The
incidence rate distribution of brain cancers, as shown in Figure 4, is dominated by patients over
50 years of age, so it is expected that a simultaneous increase in the demand for treatment will
also be observed. This suggests that the already large market is, therefore, growing as well.
The total market for treating edema is based on the annual revenue gained from the sale of DXM
to brain cancer patients. To determine the total value of the cerebral edema treatment market, it
is necessary to identify how many customers purchase DXM annually, the total treatment time
for cerebral edema, and the drug dosage amount needed during that time to provide therapeutic
effect. The range of treatment time for brain cancer can vary between 4 and 12 months, but it
will be conservatively estimated that treatment for vasogenic edema associated with brain cancer
can last 4 months. This estimate is based upon many factors, such as the extent of edema caused
by the tumor. The required dosage needed for a patient suffering from edema can also vary,
depending on the severity of edema and how the patient responds to treatment. A typical dosage
administered via IV can be estimated as 16 mg/day for the first 5 days, then tapering the dosage
every 5 days, four times, by 4 mg. This means that the monthly dosage rate is calculated as
follows:
Table 1: Calculation of Human Monthly Dosage Rate
Dosage Rate (mg/day)
Days 1-5 16
Days 6-10 12
Days 11-15 8
Days 16-30 4
Total Dosage Rate (mg/month)
240
Table 1 only calculates the dosage regimen for systemic administration. The effective
therapeutic dosage for local delivery, however, has yet to be accurately determined. It is
assumed that the effective dosage is primarily dependent upon the plasma binding affinity of
DXM. It is 0.77, in this case, which means that 77% of the delivered dosage is bound to protein,
whereas the remaining 23% of the dosage is free to provide therapeutic effect - assuming that the
total drug reaches the desired delivery site (i.e. drug concentration at the desired site reaches
therapeutic levels). Therefore, the total DXM payload should be approximately 221 mg, based
on the plasma binding coefficient, systemic dosage, and total treatment time. Assuming
hospitals charge the same price to patients as pharmacies, the cost of pure concentration DXM
can vary between $0.42/mg and $1.00/mg, depending upon the size of the total purchase25 . This
means that the estimated cost of DXM is between $93 and $221 per patient for one year. The
following calculations regarding the local drug dosage and corresponding cost will be used in the
latter part of this market analysis. The current total cerebral edema treatment market, which in
majority uses DXM via IV or oral administration, can be calculated using the total dosage rate
from Table 1 and the total treatment time (e.g. 4 months). The total drug dosage required is
approximately 960 mg, so this is charged at an annual cost between $403 and $960 per patient.
Finally, this means the annual valuation of the total edema treatment market is between $80.6
million and $192 million, if every patient diagnosed with brain cancer in the U.S. is indicated for
DXM. To put the cost of the drug (per patient) into perspective, a common chemotherapeutic
drug, called Temozolomide, used in treating recurrent brain metastases and glioblastoma
multiforme, a malignant late stage brain cancer, over the same time period costs more than
$6,30026.
There are still a few remaining aspects or issues that need to be considered in order to establish
how the innovation will fair in the marketplace. These include the cost associated with the
morbidity of DXM use and competition from other commercially available technologies.
2.4 Estimated Cost of Product & Market Competition
The price of a new medical innovation is influenced by several important factors. These include,
development costs (e.g R&D, FDA approval, intellectual property protection), production costs
(e.g manufacture, scale-up), potential market size, pricing of comparables, pricing of
commercially available components of the device, and expected profit margins19 . Some of these
influences are explored here.
Oncologists would adopt the proposed innovation as a standard treatment option, if the proposed
innovation circumvents the side effects of DXM, while providing an equally therapeutic effect
(i.e. restore the BBB to reduce vasogenic edema) as the systemic administration of DXM. This
will improve a patient's quality of life and eliminate the need for a complex treatment regimen
that requires a longer treatment time (i.e. more days spent in the hospital).
One way to estimate the cost of morbidity associated with DXM, or the cost of treating the side
effects associated with the long-term use of DXM, is to first identify complications that are
exhibited by patients. For example, these can include pneumocystis jervecii pneumonia,
gastrointestinal complications (i.e. peptic ulcers and upper GI hemorrhage), osteoporosis,
insomnia and anxiety, but it is important to note that not all patients may present with these
symptoms. The costs of pharmaceutical treatments for these side effects are calculated in the
table below.
Table 2: Total Cost of Current Treatment
Dosage Unit Cost of Total
Systemic Complication Name ofDrug Regimen Drug Cost of
(mg/day) ($/dose) Drug ($)
Anxiety Paroxetine HCl 20 0.47 56
GI Complications
(peptic ulcers & upper Tagamet 200 0.37 44
GI hemorrhage)
Insomnia Flurazepam HCl 30 0.7 84
Alendronate Sodium 10 2.35 282
Osteoporosis Calcium Supplement 1500 0.11 14
Vitamin D 800 0.04 5
Supplement IU/day
pneumocystisjervecii Trimethoprim- 160-800 0.67 80
pneumonia Sulfamethoxazole
Cost of $565
Morbidity
Cost of
Systemically $960
Administered
DXM
Total Cost of
Current $1,525
Treatment
The unit costs of each drug treatment were found using drugstore.com and the type of drug and
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the dosage regimen were determined using the following references . It was assumed for the
sake of simplicity that no drug interactions exist, the treatment time is four months, and generic
drugs are used. The limitations of this cost estimation is that not all of the medical problems
listed in the table are the most common, and it does not include the cost of prophylaxis and non-
pharmaceutical treatment. Considering the total cost to the patient would include the cost of
systemically administered DXM, then this would increase the total cost of current treatment by
as much as $960 to $1,525.
If the design is assumed to be a modified version of an Ommaya reservoir, using a top-down
approach, one can roughly determine the expected price of the device by taking into account the
prices of each component, and comparing these prices to competing technologies and the cost of
current treatment (systemically administered DXM and treatment of DXM-induced morbidity).
Table 3: Estimated Cost of Proposed Device's Components
Dexamethasone
CSF Ventricular Intraventricular Sodium Phosphate Estimated Total Price
Reservoir Catheter (Local Drug Delivery Additional Cost
for 4 months)
$20 $1 $221 ~$242 $484
In regard to the table above, Integra Lifesciences Corporation manufactures the CSF ventricular
reservoir. Both the price of the intraventricular catheter and the price of the CSF ventricular
reservoir were estimated based on similar items sold through eBay Inc. An additional cost was
estimated based on the assumption that the development and production costs would be reflected
in a 100% increase in the original price (i.e. $242) of the three components. Therefore, the cost
of the new medical device to the end-user or patient would be approximately $484. This value,
however, does not include profit.
One may argue this device competes with drug manufacturers who provide treatment for the side
effects of DXM and other emerging pharmaceutical products (alternatives to DXM). The more
relevant competing technologies, in this case however, are medical devices that could be used or
slightly modified to manage or treat vasogenic edema. None of these devices, at least currently,
treat vasogenic edema, but they still pose a threat as competing technologies. This is because
manufacturers of these devices possess the technical expertise and resources, such as supply
chain access and prior infrastructure investment, to easily modify or alter their device(s) to treat
cerebral edema. The specific types of technologies that will be evaluated in this paper can be
divided into four main types of approaches: intracranial, intraventricular, intrathecal, and
intranasal. These approaches describe how a competing technology can access the CNS, so as to
deliver drug or manage ICP. This will be further explored in the "Technical Analysis" section of
this report.
Two competitors that produce such technologies include Medtronic, Inc. (Minneapolis, MN) and
Codman & Shurtleff, Inc. (Raynham, MA). The prices that competitors charge for their
successfully adopted devices provide a relative price range within which the novel device must at
least fall under in order to remain competitive and qualify for healthcare reimbursement. The
markets of the potential competing technologies, however, are not the same as the one being
targeted by the device discussed in this paper, as they each treat different medical problems.
Table 4: Itemized Cost for Competing Technologies
Cost of
Device Type Manufacturer(s) - Cost of Surgical TotalDevice Device ($) Implantation Cost ($)
__________________($)
Convection- Medtronic, Inc. - 11,200 5,000 16,200
Enhanced Delivery SynchroMed@ II 1120500 1,0
Shunt Codman & Shurtleff, ~4,200 ~2,400 6,600Inc. - Hakim@
Convection-enhanced delivery uses a pump to deliver drug via an intrathecal catheter, whereas a
shunt is a device that diverts excess CSF to another part of the body for excretion or uptake.
Surgical implantation costs include the neurosurgeon's services, anesthesia, and disposable
medical supplies used in the procedure. All costs listed in Table 4, are prior to insurance
reimbursement. Costs for the shunt were based on the Euro in 2003, which were converted into
current U.S. dollar values. To adjust for the difference in cost between the U.S. and Europe, it
was assumed that medical care in Europe costs 50% less 28,29,30,31,32
Both competing technologies - drug pump and shunt - are at least an order of magnitude greater
in cost, compared to the estimated cost of $484 for the new device. This means that if the new
device is sold at a price similar to its competitors, then it could yield a significant profit margin.
The surgical implantation cost for the new device is expected to be even lower than for the shunt,
because the implantation procedure is simple. It merely requires the intraventricular insertion of
a ventricular catheter and a subcutaneous implantation of a reservoir. If the patient's tumor were
operable and resected, the surgical implantation would require no additional cost, because the
tumor's resection and the new device's implantation could be done simultaneously. An
estimated total cost of the device is itemized in the table below.
Table 5: Itemized Cost Estimate of Proposed Device
Cost of Device Cost of Surgical Total Cost($) Implantation($
484 0 or -1,500 484 or 1,984
The higher estimated price for the novel device ($1,984) is less than a third of its competitors,
but only if the tumor is operable, would it also be less ($484) than the total cost of current
treatment ($1,525). Even if the higher estimated price were charged to the patient, the improved
quality of life that the new device offers is far more important than the slightly additional cost
that they must incur. This clearly supersedes any conclusion made by a cost analysis of any new
medical treatment.
A final, yet important, consideration is the profit margin that can be expected from
commercializing the proposed device. An expected profit margin can be estimated based upon
the average profit margins of drug and medical device manufacturers. It would be more accurate
to estimate an expected profit margin using data from small, medical device startups that offer a
similar product and use a similar business model. This data is, unfortunately, unavailable, but
one independent, investment research company found that generic drug manufacturers, like those
that produce DXM, have a profit margin of 6.5%33. Using the EDGAR Securities & Exchange
Commission database with financial statements of publicly held companies 34, an annual financial
statement of Medtronic, Inc. was used to determine the profit margin for a successful, competing
medical device manufacturer. The average profit margin of Medtronic, over the past five years
and since 2009, has been approximately 18.9%. Although Medtronic produces several different
types of medical devices, it can be assumed that this profit margin is the same for individual
products. This means the profit margin for the hybrid drug-device product should fall
somewhere between the range of 5% and 20%. This range also represents the return on
investment that investors should expect, once the innovation has gained enough momentum.
3 Implementation Analysis
3.1 Regulatory Approval
One of the major market barriers for a medical product startup is obtaining government approval
prior to its sale to patients. It can be financially burdensome, primarily due to the high cost of
clinical testing, and the time it takes to gain approval can take several years (i.e. > 8 years). In
the U.S., the Food & Drug Administration (FDA) regulates new medical devices, drugs and other
medical products. The FDA would classify the new medical product as a drug-device
combination product, which means it will most likely be assigned by the Office of Combination
Products (OCP) to be reviewed by the Center for Drug Evaluation and Research (CDER). This
is anticipated because according to 69 FR 25527, the primary mode of action (PMOA) of the
combination product is that of the drug. It provides "the greatest contribution to the overall
"35intended therapeutic effects of the combination product"
A combination product is comprised of more than one regulated component (i.e. drug, device,
biologic), and the FDA can sometimes require a separate premarket application for each
component. The determined PMOA does not dictate the type of premarket application that must
be submitted, but it is anticipated in this case that a single marketing application will be
sufficient to obtain approval. According to the Intercenter Agreement between the CDER and
the Center of Devices and Radiological Health (CDRH)36, the combination product is best
described as a "prefilled delivery system," which means the market approval authority would be
the CDER, where device authorities from CDRH would be consulted.
A new drug application (NDA) must be submitted under Section 505(b)(2), despite the fact that
dexamethasone sodium phosphate is a generic drug. It is a pathway to approval that can
potentially save both time and money. It is used in the case where a drug has been previously
FDA approved, but with one or more of the following modifications:
e Changes in dosage form, strength, route of administration, formulation, dosing regimen, or
indication;
e A new combination product where the active ingredients have been previously approved;
e Change to an active ingredient (e.g., different salt, ester complex, chelate, etc);
e New molecular entity when studies have been conducted by other sponsors and published
information is pertinent to the application (e.g., a pro-drug or active metabolite of an
approved drug);
e Change from an Rx (i.e. prescription) indication to an OTC (i.e. over the counter) indication;
e Change to an OTC monograph drug (e.g., non-monograph indication, new dosage form);
e A drug with naturally derived or recombinant (i.e, biological) active ingredients where
additional limited clinical data is necessary to show the ingredient is the same as the
ingredient in the reference drug;
e Bioinequivalence for drug products where the rate and or extent of absorption exceed or are
otherwise different from the standards for bioequivalence compared to a listed drug 37.
The NDA under 505(b)(2) would file for changes in strength, route of administration and
formulation for the new product. The advantage of this type of application is that it can partially
rely on the FDA's previous findings (i.e. preclinical and clinical data) for safety and
effectiveness when DXM was first approved. Published literature may also be used. Compared
to a 505(b)(1) application for a completely new drug, this translates to cost savings and a
reduction in the time it takes for the new product to reach the market - approximately 3 years3 8.
The CDER review committee will determine if and what preclinical and/or clinical data will be
needed, according to 21 CFR 314.54, so it is difficult to accurately estimate the cost associated
with obtaining that data.
The Prescription Drug User Fee Act (PDUFA) determines the fee charged by the FDA for
reviewing a 505(b)(2) application. The application fee is waived, for a small business or new
startup with less than 500 employees 3 9, and this translates to a further cost saving of $702,750.
In addition, the cost of preclinical trials will be more manageable for a startup, compared to the
astronomical costs associated with clinical trials. These costs will be explored in further detail in
the "Production & Development Costs" section.
3.2 Manufacture of the Device
A preliminary design of the device can be described as follows: A dome-shaped reservoir
encapsulates a compacted form of DXM powder, which is connected to a semi-rigid, polymeric
infusion or ventricular catheter at its bottom end. The catheter has a number of holes at its
proximal end, and this serves to allow CSF to flow into the catheter and allow the drug to diffuse
out of the catheter's holes. Assuming this preliminary design of the device is the final product to
be commercialized, suggestions can be made pertaining to its fabrication. The device and drug
can be divided into four separate components, in order of assembly: reservoir base, compacted
DXM drug, reservoir cap and ventricular catheter. These components are illustrated in the figure
below.
Compacted DXM Drug
Ventricular Catheter
0 0 0j
Reservoir Cap Reservoir Base
Figure 5: Illustration of Preliminary Design of Novel Device - Not to scale or technically accurate
The reservoir cap can be affixed to the reservoir base with a medical-grade adhesive, and the
catheter can be affixed to the nozzle of the reservoir base. However, during surgical
implantation, the neurosurgeon may need to carefully insert the catheter, without the reservoir
obstructing his/her view. The catheter could, instead, be modified to affix to the reservoir base's
nozzle by a mechanical fixation (i.e. tight or snug fit of catheter inside nozzle core). This may,
however, increase the risk of dislodgement, compared to the adhesively bonded design.
A likely manufacturing process for medium scale production - the order of 103 to 104 - is
suggested here, based upon the primary components that comprise a preliminary design of the
hybrid drug-device and assuming it is production-ready. The figure below is a process flow
diagram that indicates its key steps.
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Figure 6: Process Flow Diagram of Key Manufacturing Steps
The diagram is, first, divided into two different, pre-existing process lines. The one at the top of
Figure 6 illustrates the fabrication of the compacted DXM drug. The other line below illustrates
the fabrication of the device's remaining components (i.e. reservoir cap, reservoir base and
catheter). These process lines also represent pre-existing supply chains (i.e. medical device and
pharmaceutical) that are connected to a new one. It is assumed that these processes are
conducted within manufacturing facilities that have been certified as meeting the FDA's current
good manufacturing practice (cGMP) standards.
Fabrication of the compacted DXM: First, raw materials are collected, including DXM powder,
binders, excipients, lubricants, etc. Then, these raw materials are granulated40 so as to produce a
high concentration DXM formulation with specific physicochemical properties (e.g. solubility,
dissolution rate). Granulation can include several steps that depend upon the solubility of the
ingredients, their ability to crystallize, wettability, mean particle size, etc.41. Finally, the
granulated pharmaceutical formulation is compacted using a tablet press40 , but it must have
similar dimensions and shape as the reservoir so that it may be properly encapsulated.
Fabrication of the device components: Raw materials are collected, primarily polymer resin that
can produce, for example, polyurethane or polysiloxane (i.e. silicone). These polymers are
suggested because they are both commonly used for long-term, in vivo catheters42, and Professor
* *Sterilization Packaging
Cima's laboratory group is currently investigating silicone as a possible semi-permeable
membrane for the device. Then, using pre-fabricated metallic molds, the three remaining
components of the device are injection molded. There are several forming processes to choose
from, but the one that is chosen will depend upon the desired production rate and the cost that
can be afforded43
The final steps include assembling the components, as explained previously, in a clean room
environment. This is followed by sterilization using ethylene oxide gas, irradiation, or high-
intensity pulsed light40 . The chosen technique will depend upon the sensitivity of the
components used, such as the tendency for polymers and drugs to degrade after exposure to
radiation. It is then vacuum-sealed in a polymeric package, prior to distribution. This is to
reduce the amount of moisture or air that could potentially cause any one of the components to
become contaminated or prematurely decompose during its shelf life.
The manufacturing process - the key fabrication steps and equipment needed - such as the one
previously explained, is dependent upon two major factors, the demand for the product or
production volume and the design of the device.
3.3 Patent Protection
It is essential to protect new ideas related to the innovation, prior to approaching potential
partners or licensing the technology. One must first determine whether the new ideas are
patentable. Certain aspects of the device proposed in this paper are novel, useful and unobvious.
A patent portfolio, in regard to the preliminary device design used in the suggested
manufacturing process, should primarily protect the following: the incorporation of solid drug in
an Ommaya/implantable reservoir, the intraventricular catheter design (e.g. materials and
dimensions), the novel pharmaceutical formulation of the solid drug, and fabrication processes
needed to make the final product.
The cost of filing a non-provisional patent can burden a startup with its high cost, especially in
its early stages. A provisional patent is not only significantly cheaper to file - on the order of
hundreds of dollars - but it also provides the innovator two years until a non-provisional patent
must be filed, by which time all the details of the patents should be known, and several iterations
of the innovation process will show whether it is worth further pursuit.
Timing is also an important aspect when it comes to filing for patent protection. Determining
when each patent should be filed depends on a few factors. The current status and expected
progress of research related to the development of the device, such as its performance in
preclinical tests. The patent application also depends on when it will be decided to approach
investors and/or collaborators to commercialize the device. An expected progress timeline that
suggests when all of these events should occur will be presented at the end of this section.
Identifying prior art associated with the patentable innovation is a necessary step. It recognizes
complementary IP that has helped comprise the novel innovation, and it defines the boundaries
of the new IP domain. This means prior art is used to show what specific claims are and are not
protected, which in turn dictates what claims can be made in the novel device's patent
application. A general search was conducted for relevant patents based on the preliminary
design of the device. These patents were found using the United States Patent & Trademark
Office (USPTO) online database and are listed in the table below.
Table 6: List of Prior Art Patents
Patent No. Patent Title Brief Description Issue Date
Drug-Related Patents
Synthesis of Steroid Original preparation method for2,939,873 Phosphates Dexamethasone Sodium Phosphate June 7, 1960
compound
Solid Pharmaceutical Formulation of high concentration6,299,904 Formulation DXM in solid, compacted tablet October 9, 2001
form
Reservoir-Related Patents
Surgical Reservoir for Original design of subcutaneous,
3,310,051 Implantation Beneath the Ommaya reservoir March 21, 1967
Skin
Implantable Refillable Same as previous patent - renewal
5,836,935 Controlled Release Device to of protection and more detailed November 17,1998Deliver Drugs Directly to an claims, such as use of permeable
Internal Portion of the Body catheter
Catheter-Related Patents
Design & fabrication process for
ventricular catheter with
4,767,400 Porous Ventricular Catheter polyurethane membrane permeable August 30, 1988
to CSF
Angled Hole Ventricular Design & fabrication process for
4,784,638 Cathe er anV eethod of ventricular catheter with angled November 15, 1988C athete amehdo holes to prevent brain tissue
blockage
Angled Hole Ventricular Same as previous patent but with5,180,387 Catheter with Non-Circular triangular bore shape January 19, 1988
Bore
Catheter with scalloped opening at
5,531,673 Ventricular Catheter distal end to prevent blockage by July 2, 1996
brain tissue I _I
The reservoir and catheter patents do not include integrated mechanical, electrical or chemical
mechanisms that control drug release. Instead, the drug's formulation will control its release or
dissolution rate. It has not yet been determined whether a different type of approach to
controlling drug release will be needed. If such a mechanism will be incorporated in the device,
a new patent search must be conducted. The catheters listed in the table are intended to show
different types of designs that could be adopted and modified, depending upon the technical
demands of the device.
The original patents for the subcutaneous reservoir and DXM drug were also included, even
though their patent protection has long expired.
A patent search for technology that aims to treat cerebral edema can be invaluable to the
innovator. Patented technology, in contrast to new technology shared in journal publications, is
more likely to be commercially pursued. This means patented technology that aims to solve the
same problem as the innovator's device are also competitors. The main difference these
competitors have with those previously discussed is that they do not have a commercially
available product. Some of the most recent and relevant patents, both issued and under
application, are tabulated below.
Table 7: List of Issued, Competing Patents
Issued Patents
Patent No. Patent Title Brief Description Issue Date
Polymeric Device for Biocompatible polymeric carrier matrix February 11,
5,601,835 Controlled Drug Delivery that offers desirable drug release kinetics 1997
to the CNS
Intraventricular or intracranial drug
5,720,720 ConvectionEnhanced Drug delivery by microinfusion with catheter Febru 24,Delivery and drug pump
Anti-inflammatory-agent- Catheter that could be used for
6,110,155 loaded Catheter and Medtronic's drug pump to August 29, 2000Method for Preventing intraventricularly deliver drug
Tissue Fibrosis
6,168,801 Controlled Release Drug Biodegradable silicone particles used 
as
8 C Delse D a drug carrier and to control drug release January 2, 2001
B 1 Delivery rate - demonstrated for DXM
6,180,603 Method for Administrating Intranasal delivery of drugs via olfactory6 0 Neurologic Agents to the neural pathway and its necessary January 30, 2001
B1 Brain pharmaceutical formulation
Programmable Implantable
7,192,414 Pump with Accessory Implantable pump system with multiple7 2 Reservoirs and Multiple drug reservoirs that uses catheter as a March 20, 2007
B2 Independent Lumen conduit for delivery
Catheter
7,596,408 Implantable Medical Subcutaneously-implanted device with September 29,
B2 Device with Anti-Infection anti-infection coating and multiple 2009
Agent capabilities, including drug delivery
Table 8: List of Filed, Competing Patents
Patents Under Application
Publication Patent Application Title BriefDescription Filing Date
Methods and Apparatus for Enhanced
and Controlled Delivery of a Device for iontophoretic (i.e. December 5,
10/051,817 Biologically Active Agent into the non-invasively through skin) 2002
Central Nervous System of a delivery of drug to CNS
Mammal
Controlled drug delivery
11/200,749 Method for Delivering Drugs to device with reservoir and August 10,Tissue under Microjet Propulsion energy source to drive 2005
propulsion
Enhancement of Drug Delivery to the Intraocular drug delivery and December 6,11/951,748 Central Nervous System its necessary pharmaceutical 2007formulation
Implantable, matrix-
12/459,779 Drug Delivery Systems Based on controlled diffusion drug November 5,Cationic Siloxanyl Macromonomers delivery system using 2009
inorganic polymers
The commonality between these patented designs is that they can provide local drug delivery to
the brain for at least four months. Most of them also mention that DXM can be used as the
pharmaceutical agent. This means these patents can be considered competing technologies that
have not yet been commercialized, but still pose a threat in the long term. These patents also
differ from each other in terms of their intended site of implantation or delivery, and the method
by which they deliver drug. Intraocular, iontophoretic, and intranasal drug delivery are not yet
commonly used in the clinical setting, so their successful commercialization is expected to take
longer than technologies using intraventricular or intracranial approaches. Furthermore, a
controlled drug release rate is more desirable than a bolus infusion of drug, which most of the
competing technologies also seem to demonstrate.
In light of the trend of patented technologies that aim to address CNS drug delivery, the patents
identified in Tables 7 and 8 could also serve to define IP territory that the innovation may move
towards as well.
Note: Microchip drug delivery patents were not included here, because the innovator of that
device is Professor Cima, who is the same innovator of the device discussed in this paper.
3.4 Supply Chain Strategy
Integration of the startup into the existing supply chain is another important aspect of
implementation. This includes the device's adoption by hospitals or physicians, and
collaborating manufacturers. Efforts to commercialize this device should focus on the supply
chain strategy of the startup, or in other words, how it can become a successful member of the
supply chain amongst the crowd.
Below is an illustration of the current U.S. healthcare supply chain structure, so as to show how
the healthcare supply chain is connected and what parts of it are most relevant to the proposed
device.
Figure 8: Linear Version of Healthcare Supply Chain
The "suppliers," "manufacturers" and "distributors", as shown in the figure above, can often be
represented by one company, such as Medtronic, Inc., who then sell their product to GPOs or
hospitals.
Outsourcing specific aspects of a startup business can help it focus on its strengths and utilize
pre-existing supply chains. The startup will also be better able to manage its total financial risk,
in comparison to making a large capital investment for an in-house operation. However, it
would be a mistake to completely rely on outsourcing and licensing as a means to make profit.
A lack of involvement on the part of the startup will leave the outsourcing business no incentive
to pursue an improvement in its already profitable product line. A possible strategy is to
outsource all aspects of production and development, except for preclinical and clinical (if
necessary) trials, device assembly, and new research and development (R&D). The startup
would have expertise in obtaining supporting evidence for the FDA application and pursuing
new R&D. Although constructing a clean room for device assembly may initially seem to be a
large financial risk, it is necessary. It helps to be involved and invested in a part of the
manufacturing process in order to become an active part of the supply chain. It is also
advantageous in that it is the only step that requires the least capital investment and the least
expertise, in comparison to the other manufacturing steps.
A distribution, marketing and sales team would also be formed to sell the product directly to the
end-user, physicians and GPOs. However, it is not a strength that the startup would have and
this would require a large number of sales representatives and promotions (i.e. free products) so
as to market the new product across all levels of the supply chain. The benefit of an in-house
distribution, marketing and sales team would be that the startup would gain feedback from all
parts of the supply chain, and so would be able to improve the existing product as well innovate
new ones.
The improved patient prognosis that this proposed device offers will certainly attract interest
amongst many physicians. It is essentially a modified version of an Ommaya reservoir, which
would facilitate its successful adoption in the clinical setting. Its use is a well-known and
accepted form of therapy.
.............................. .................... ............................. 
3.5 Business Model
Three important aspects of any successful business strategy are: partnering, licensing and
litigation. These aspects must be carefully considered in the context of the discussion thus far.
One possible strategy, once the device is production-ready, or in other words, ready for launch
outside the academic research environment, is to first file a provisional patent for the
ideas/inventions discussed in the "Patent Protection" section. This is a cheap option that should
be done prior to filing for FDA approval. Filing for an FDA 505(b)(2) application and
conducting preclinical trials should then be pursued, and once approval is obtained, partners will
need to be sought to outsource most of the manufacturing process. Partnering deals may need to
involve a licensing agreement, whereby the device or any of its components may not be sold to
any other entity not included in the agreement. For example, if a drug manufacturer is producing
the compacted DXM drug for the startup, then it cannot sell it to any other member of the supply
chain, unless a royalty is provided in exchange for that transaction. Some deals may even
involve cross-licensing, whereby both parties protect their IP in the deal. For example, if the
drug company has invested and patented its technology for producing the compacted DXM drug
and the startup owns the patent for producing the device that will use that drug, then both parties
need to respect those claimed IP rights (i.e. startup should not make the compacted DXM drug
by using the patent from the drug manufacturer and vice versa). Should any of these partnering
deals falter as a result of a patent infringement, threat of litigation would be the initial response.
In the suggested supply chain strategy, after in-house assembly and the product is sterilized and
packaged, the device could then be marketed and sold to GPOs and hospitals. The intent here is
to convince them that the device offers an improved quality of life for patients, whom both GPOs
and hospitals are heavily influenced by.
In short, due to its many attributes, the device is expected to maintain its market share. It can
provide a simple and effective solution, unlike its competing technologies. This means that both
patients and physicians will prefer it. Marketing aimed at hospitals or physicians will also help
to maintain the device's market share. Collaborating with or gaining product-related feedback
from physicians may also help to improve the device.
3.6 Expected Timeline
An expected timeline for the product to reach market, based on a 20-year patent, is outlined in
the figure below.
Proof of Utility PatentPofcoftIssued FDA Approval
Concept&&
l PBegin FDA ProductFile Patent Application Launch
1yr ~'3 yrs ~3 yrs ~14 yrs
idea Preclinical/Clinical Trials, Patent Expiry
Seek Funding,
&
Approach Suppliers
Figure 7: Expected Timeline for New Product
Approximate times are suggested as to when specific events, such as patent filing and
commencement of preclinical/clinical trials, should be pursued. The timeline also indicates an
approximate completion time for relevant events. The purpose of this timeline is to help
minimize the time it takes for the final product to reach the market and to maximize the time it is
commercially available, while under patent protection.
3.7 Production & Development Costs
An estimate of the financial investment necessary to start a company based on the innovation is
presented.
Assumptions:
* Clinical trials are unnecessary for FDA approval,
* 248 days of production in one year (96 weekend days, 21 days of unpaid vacation) and all
employees work 8 hours per day,
* Components are large enough to be assembled by hand, and therefore do not require any
additional tooling or equipment to assemble the final product.
The table below presents an itemized list of the most relevant costs, based on the recently
discussed supply chain strategy and business model.
Table 9: Research, Development and Manufacturing/Product Assembly Costs
Research & Development
Equipment and Capitalt
(Lab Space of 2000 sq. ft. with $750,00044'45
supporting equipment)
Employees
(Engineers = 2 x $70k/yr) $280,00046
(Scientists = 2 x $70k/yr)
Preclinical Testing' $260,00045
TOTAL $1,290,000
Manufacturing/Product Assembly
Clean Roomt
(2000 sq. ft., ISO 4, $3,100,00047
Low Sidewall, Gown-up Room)
Employees
(Line Supervisor = $29/hr) 46
(Assembly Line Workers = $208,000
5 x $30k/yr)
TOTAL $3,308,000
Table 10: Distribution, Marketing, Sales and Other Costs
Distribution, Marketing & Sales
Distribution $1,000,000(Estimate)
Promotionst
(~2,000 Devices or 1% of total $1,000,000
market size at -$500/device)
Employees
(Sales & Marketing Reps = $1,200,00046
20 x $60k/yr)
TOTAL $3,200,000
Other Expenses
Utilities
(0.1 -kW/sq. ft.) $24,00048
($0.03/kWh, 1984 hrs/yr)
Disposable Laboratory Supplies $120,00041
Filing for Utility Patent and 00,00045
Other Legal Feest $2
TOTAL $344,000
Table 11: Total Estimated Startup Cost
Research & Development $1,290,000
Manufacturing/Product Assembly $3,308,000
Distribution, Marketing & Sales $3,200,000
Other Expenses $344,000
TOTAL $8,142,000
The itemized list of both fixed and variable costs does not include the costs of the individually
purchased components, and the costs associated with sterilization and packaging. This is
because one would need to conduct a completely separate analysis of those supply chains to
determine the costs that would be incurred to produce the novel components. One would then
need to estimate how much the components would be sold for to the startup based on the
resources and expertise that were used. Other regulatory costs, such as establishment and
product fees were also not included. Definitions of these applicable fees can be found here49.
The total production cost for the first year of the startup is approximately $8.14 million. The
minimum cost that will be passed on to the end-user, or assuming the entire market is captured -
clearly unrealistic - within the first year would be approximately $40.70 (i.e. $8.14 million /
200,000 patients). Although this is an order of magnitude less than what the device is expected
to sell for, annual production costs are expected to decrease to -$2.83 million. This means that
the new minimum cost passed on to the customer would be $14.10.
The more realizable cost passed on to the end-user will depend on the captured market share. If,
in the first year of production, the captured market share is equivalent to the number of patients
diagnosed with brain cancer in the state of Massachusetts, then the cost of producing each unit
could be estimated. According to the National Cancer Institute, in 2006, the incidence of brain
cancer was approximately 25,000 (i.e. 12.5% of total market), which translates to a unit cost of
~$325 (i.e. $8.14 million / 25,000 patients) per device. Assuming the remaining cost of the
product is primarily dependent upon the cost of the components, it can be estimated to be $242 -
same value used to calculate unit price charged to patient in the "Market Analysis" section. The
total unit cost would then be $567 per device in the first year. If this market share grows by 10%
per year (i.e. 27,500 in second year) and the annual production cost drops to $2.83 million, then
the new unit cost would be $345. This is also assuming the unit cost of the components remain
unchanged (i.e. $242) and is included.
3.8 Sources of Funding
Without any kind of financial support, this project would cease to progress. It is therefore vital
to consider where funding must be sought as the project evolves. The type of funding that is
sought depends upon the timeline of its progression. The project is currently in its early stages of
academic-level research, which demands proof of concept or demonstrating that the device's
design is technically feasible. Funding for this type of research would originate from the
National Institutes of Health (NIH), a government-funded agency that supports medical research
that aims to improve human health. Funding allocation for brain and CNS research by the NIH
has increased by more than 30% between 2004 and 200850, so this is a positive indication that
funding from this source is abundant. Once the research shifts to preclinical testing and the
transition to industry begins, a possible source is the Small Business Technology Transfer
Program (STTR) - more details can be found here. Once sufficient preclinical and clinical data
has been collected for FDA application and a small-scale or pilot plant facility is desired, then
seed investors should be sought, such as angel investors and even personal investors (i.e. family,
friends, colleagues, partners). If FDA approval is then obtained and a sufficient market share has
been captured, then scale-up to a medium or large size facility could be funded by venture
capitalists. In the long term, acquisition can also become a possibility by a competing or partner
medical device manufacturer, such as Medtronic.
4 Technical Analysis
4.1 Brief Introduction to Drug Delivery
Most drugs are engineered to provide therapeutic effect to a specific site within the human body.
Their clinical effectiveness from a pharmacokinetic (i.e. effect of body on drug) standpoint is
dependent upon their drug delivery characteristics, particularly their duration of release, site of
administration, and method of administration.
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compliance with dosage regimen requirements". The prolonged release system, in contrast,
"(extends the release of the drug by, for example, slowing the dissolution rate of the drug" 52 . The
controlled release system differs in that it maintains a uniform drug concentration at therapeutic
levels by dispensing a constant amount of drug throughout the dosage time.
There are two types of controlled-release systems. One type is a reservoir device, like the
innovation described in this paper, whereby drug is loaded and stored in a reservoir in either a
liquid or solid form. A semi-permeable membrane or a small orifice allows the drug to then be
delivered by means of permeation or diffusion, respectively. The second type of device is a
matrix diffusion device, whereby "drug is dispersed evenly in a solid matrix"5 2 . Drug release
can either be controlled by "dissolution of the matrix with corresponding release of drug, or
diffusion of the drug from the insoluble matrix"52 . The design of such devices requires more
attention to their physicochemical properties, such as solubility and stability, and the formulation
process.
Many drugs are delivered orally or intravenously, so as to reach the diseased tissue or organ via
the systemic bloodstream. Drugs, such as DXM, however, can have toxic systemic effects.
Metabolism or a low bioavailability of the drug can also require a higher percentage of the active
pharmaceutical ingredient per dose. Targeted or local drug delivery is often used to circumvent
systemic toxicity and increase the drug's potency. Sites that are relevant to drug delivery to the
CNS, as previously mentioned in the "Market Analysis" section, by means of a controlled release
device are intracranial, intraventricular, intrathecal, and intranasal. The available methods by
which drug can be delivered via these sites are plentiful, and will be evaluated in the latter part of
this section.
4.2 Barriers to Drug Delivery
A major difficulty in delivering drugs to the central nervous system is the presence of certain
physiological barriers that manage to protect the brain from foreign molecules, including drugs,
while preserving nutrient uptake. The physicochemical and biochemical properties of a drug
molecule dictate how it interacts with the barriers of the CNS. A drug's interactions with these
barriers are typically predicted through modeling of its pharmacokinetics and pharmacodynamics
(i.e. effect of drug on body). The drug is then manipulated, based upon these models, to
optimize its delivery or interaction with these barriers5 2. For example, a typical evaluation
scheme for improving the oral bioavailability or the plasma drug concentration in systemic
circulation of a drug candidate is depicted in the figure below.
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Figure 9: Evaluation Scheme for Oral Drug Candidates2
4.2.1 Blood-Brain Barrier
One of the major barriers to the CNS is the BBB. Its physiological functions include
"maintenance of [the] neuronal microenvironment, tissue homeostasis, vasotonous regulation,
fibrinolysis and coagulation, blood cell activation and migration... [and] vascularization of
normal neoplastic tissues" 3 . To regulate the proper function of all these processes, specific
mechanisms of the BBB selectively filter out molecules, including drugs, from the brain's tissue.
The ones discussed below are the most relevant to the delivery of DXM.
Most systemic capillaries are lined with fenestrated endothelial cells that permit free exchange of
cells, molecules and ions between the blood and surrounding interstitium. However, the cerebral
microvasculature of the CNS is lined with endothelial cells "fused together by pentalaminar tight
junctions" 54, which impede the transport of most molecules or drugs with a molecular weight
greater than 500 Da. To put this in perspective, the average molecular weight of DXM is 516
Da. The electrical resistance of the BBB is also 2-3 orders of magnitude higher than systemic
endothelial cells (1000 Qcm 2 vs. 5-10 Qcm2), which also impedes the transport of ionically
charged molecules.
There is a "marked deficiency in pinocytic vesicles"5 4, in comparison to the systemic
microvasculature. This means that transcytosis, an important means of extravasation of
molecules, occurs less often in cerebral endothelial cells. This further reduces the transcellular
transport of drug molecules.
The BBB exhibits a high lipophilicity due to the "continuous layer of lipids" 5 4 of the brain's
capillary endothelial layer. Most drug molecules, in contrast, are water soluble or hydrophilic
and as a result, their transport through the BBB is further impeded.
The BBB also contains a "higher concentration of the P-glycoprotein active-drug-efflux
transporter protein" 4 . This actively removes drug molecules from the endothelial cell cytoplasm
before they can provide any therapeutic effect.
4.2.2 Blood-Cerebrospinal Fluid Barrier
CSF circulates within the brain's ventricular system, which includes the subarachnoid space as
well as the lateral, third and fourth ventricles. It is also produced and secreted by the choroid
plexus. Considering the "CSF can exchange molecules with the interstitial fluid of the brain
parenchyma"5 4, a blood-cerebrospinal fluid barrier (BCB) exists to regulate the transport of
blood-borne molecules into the CSF5 3. A few of its mechanisms that selectively filter out drug
molecules, particularly those that are relevant to DXM, are discussed below.
The epithelium of the choroid plexus is held together by "fenestrated tight junctions"5 4, which
are more permeable than the capillaries that comprise the BBB. The rate of extravasation from
the choroid capillary networks is restricted, but it is "more permeable to ions than the BBB" 54.
The BCB also actively removes organic acids from the CSF and fortunately, this does not apply
to DXM, since it is an inorganic ester.
An additional barrier that some consider to exist is the CSF-brain barrier. Despite the consensus
that the source of interstitial fluid is CSF, "substantial inconsistencies.. .between the composition
of CSF and interstitial fluid of the brain parenchyma" have been reported 54 . This is explained by
the "insurmountable diffusion distances required for equilibration between the CSF and the brain
interstitial fluid" 54. This suggests that introducing a certain drug concentration into the brain's
CSF spaces does not guarantee that a similar concentration will be found in the brain's interstitial
fluid.
4.2.3 Blood-Tumor Barrier
Drug molecules delivered systemically or through the cardiovascular system, in the case of a
CNS cancer, have been shown to encounter a barrier at the tumor site. The mechanisms that
support this blood-tumor barrier (BTB) are discussed below.
A brain tumor can disrupt the normal physiology of the BBB, as was described in cerebral
edema. In the case of low-grade primary and small metastatic tumors, however, the BBB is
"relatively intact," but in the case of "larger tumors the functional capacity of the BBB is
regionally variable"5 4. At the center of the tumor, the BBB is severely compromised, but the
BBB's functionality, particularly for a primary brain tumor, improves towards its peripheries. A
delivered drug's distribution is rendered heterogeneous or "spatially inconsistent" 54, as a result of
a variably functional BBB.
Another BTB mechanism that hinders drug delivery occurs during tumor growth. Vascular
surface area decreases and intercapillary distance increases, as a tumor grows larger. This results
in a decrease in the transport of blood-borne molecules, and an increase in the diffusion distance
required for drug molecules to reach the site of action, respectively54.
The BTB is further reinforced by the rise in intratumoral pressure, caused by edema. As the
leaky fenestrations of the BBB increase the rate of extravasated fluid at the center of the tumor,
as opposed to the peripheries, a pressure gradient forms. This leads to two unfavorable
consequences. Once the intratumoral pressure reaches the pressure inside the cerebral
capillaries, the flow of fluid will be retarded, and therefore will impede the flow of blood-borne,
drug molecules to the tumor site. The formation of peritumoral edema, which is a continuous
flow of fluid originating from the center of the tumor, can create a "constant, radially directed
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convective force diametrically opposed to intratumoral drug penetration"
The presence of these barriers provide more than enough justification for a local means of drug
delivery, so as to bypass many of the physiological barriers of the CNS and therefore provide
therapeutic levels of drug.
4.3 Drug Delivery Device Considerations
In designing a new drug delivery device, it is important to consider what characteristics it must
exhibit in order to function properly and provide therapeutic effect throughout its use.
The drug delivery device should exhibit a controlled drug release profile. The timescale of
treatment of tumor-related cerebral edema is on the order of four to twelve months, so a
controlled release device should be able to deliver therapeutic levels of drug over that desired
period of time.
To address the systemic toxicity of oral or IV DXM administration and circumvent CNS barriers,
the drug should be delivered locally to the site it is needed. Local administration also helps to
increase the drug's potency or its ability to provide sufficiently therapeutic levels of drug,
because hepatic first-pass metabolism is avoided5 5 . This translates to a smaller drug payload
(due to higher drug potency) that would be needed for the duration of the treatment.
During the long period of time the device is expected to remain in vivo or in contact with the
physiological environment of the brain, the materials used in the device should exhibit long-term
biocompatibility. This means the interaction between surrounding tissue or fluid and the surface
of the device should not induce an inflammatory response during the wound healing process56.
Similarly, the device must also exhibit minimal biofouling, or the effect the body has on the
device must be minimized. For example, if enough minerals are deposited on the orifices of the
device, this could decrease and eventually block drug flow. Another example is if proteins are
adsorbed on the surface of the device then it can become encapsulated by vascular connective
tissue - also known as fibrosis - which will "retard the transport of low-molecular weight
molecules... due to increased diffusion path tortuosity and steric hindrance"57 . A more
comprehensive and detailed discussion of biomaterials used in vivo can be found heres6
Although many devices, even for short-term drug delivery, require some form of implantation or
access across the skin layer, the ideal device should be minimally invasive. The device should
avoid causing additional harm to the patient, specifically in regard to its surgical implantation.
For example, in regard to drug delivery to the brain, it should prevent the loss of brain function
and minimize the risk of infection. The device should also provide a short post-op recovery
time, minimize feelings of pain or discomfort, and minimize scar tissue formation.
There are also other ideal design characteristics that have a lower priority than the ones
previously discussed. These include: ease of device use, ease of implantation for the surgeon so
as to miniMize the time spent in an operating room, and maintenance-free throughout treatment
so as to minimize follow-up or corrective surgery.
4.4 Methods of Local Administration & Devices
4.4.1 Intracranial, Intraventricular & Intrathecal
Drug delivery directly to brain tissue, via the brain's ventricles, or through the spinal canal is
supported by a plethora of laboratory and clinical studies. It is advantageous in many ways,
compared to systemic means of drug delivery. It bypasses the BBB and provides "immediate
high CSF concentrations" of the delivered drug. Considering the drug is also "contained within
the CNS, a smaller dose can be used"5 . Protein binding and enzymatic activity, which reduce
the effective therapeutic concentration of drugs, occur less in the CSF, compared to blood-
derived plasma. This means drugs, including DXM, will have a higher potency and longer half-
life, respectively, after they are introduced into the CSF, which "effectively minimizes systemic
toxicity"58 and minimizes the drug payload required to provide therapeutic effect throughout the
treatment time.
There are, fortunately, only a couple of disadvantages associated with using these administration
routes. The rate of drug distribution through the brain parenchyma is controlled by the tortuous
nature of the extracellular fluid space, and as a result, can be "very slow". It has also been found
to be "inversely proportional to the molecular weight of the drug"5 4 . The "high turnover rate of
the CSF (total renewal every 5-6 hours in humans)" suggests that injected drug can be "cleared
back into the blood"5 9 and can reduce the drug's distribution. Bulk CSF flow is also not
effective in transporting therapeutic levels of drug from the spinal canal to desired parts of the
brain, which explains why intrathecal administration, in comparison to intraventricular, has been
suggested to provide "limited distribution [of drug] throughout CSF pathways"6 0 . The use of
these administration methods also cause increases in ICP associated with the implantation of a
device inside the inherently small ventricular or spinal volume. This can be easily resolved,
however, by removing CSF prior to infusion or injection of a drug.
A consensus among many studies is that "continuous or pulsatile infusion" is necessary to
deliver drugs that "need to be at elevated levels for long periods" of time"5 9 . Several devices
using these methods of administration have been developed to deliver drugs to the CNS. Many
different names categorize these devices including, convection-enhanced delivery, microchips,
implantable reservoirs and biodegradable implants.
Convection-enhanced delivery (CED) is a type of device that uses a catheter and Rump to
provide a continuous infusion of drug to a desired site under hydrostatic pressure . One of the
earliest examples of such a device is the Ommaya reservoir, but its original design does not
provide "truly continuous drug delivery"54 by providing a bolus injection of drug.
Subcutaneously implanted drug pumps, in contrast, are "capable of delivering drugs as a constant
infusion over an extended period of time"54 . Commercially available examples of these pumps
include Medtronic's SynchroMed@ II (Medtronic, Inc., Minneapolis, MN) and Codman's
Codman@ 3000 (Codman & Shurtleff, Inc., Raynham, MA). However, the disadvantages of
CED delivery include: risk of "leakage, backflow and improper infusion rate" due to improper
catheter placement and poor design, "leakage of drugs in.. .non-preferred brain regions" or
healthy brain tissue where it can cause additional patient morbidity 58, "catheter-induced tissue
damage," and "logistical difficulties associated with tracing" drug distribution in the
parenchyma". CED is, nevertheless, therapeutically effective and can easily be used to deliver
DXM to the CSF spaces of the brain.
Microchip delivery, not yet offered in a clinical setting, is another type of drug delivery device
that has been suggested for use in treating brain-related disorders and diseases. Using
manufacturing techniques adopted from the semiconductor industry, multiple micro-scale
reservoirs are fabricated on a single solid-state chip, which is used to store and deliver highly
concentrated drug solutions in the form of a solid, liquid or gel18 . This MEMS-based device has
been suggested in delivering DXM 62, which makes it a promising candidate.
Biodegradable implants have been explored in great detail as a means of controlling drug release
via different types of polymer-based matrices and other drug delivery carriers (e.g. micelles,
emulsions, liposomes, nanoparticles). The most notable, commercially available version of this
device is Gliadel@ (Eisai Pharmaceuticals, Inc., Woodcliff Lake, NJ) used to treat recurrent
high-grade gliomas. It uses a biodegradable polyanhydride wafer impregnated with a
chemotherapeutic (carmustine) that is surgically implanted in the resection cavity of a tumor, so
as to deliver drug over a certain period of time. Despite its limited success as an effective
treatment, its clinical adoption is unprecedented. Its use has also been "well tolerated [by
patients,] and associated adverse effects, including increased edema, cerebrospinal fluid leaks,
and impaired wound healing" have been rarely reported60 . It is, however, "limited by modest
distribution of [drug] away from the resection cavity," and it is only available to patients with an
operable and physically confined form of disease 0 . Formulation is one of the major challenges
for drugs that have not yet been used in biodegradable implants, such as DXM. Many
physicochemical properties must be addressed by the formulation. For example, the polymer-
based matrix must degrade at a desired rate and release biocompatible particulate debris. Other
issues to consider include the site of implantation, which may not always be surgically
accessible, and a means of fixating the implant at the desired site.
A commonly used medical device that has not been mentioned yet is a shunt - comprised of a
subcutaneous one-way valve connected to a proximal ventricular catheter and a distal catheter
terminating in the peritoneum, venous system or pleural space63 . It is a device that does not
deliver drug, but rather, regulates ICP levels by draining excess CSF from the lateral or third
ventricles and diverts it to where it can be reabsorbed or excreted 64 . It is used as a temporizing
measure in treating tumor-related cerebral edema. A possible benefit to using such a device, in
comparison to drug delivery, is that it could continuously regulate and monitor ICP. This allows
for a more personalized therapeutic approach, and therefore could improve the patient's quality
of life. However, it fails to address the root cause of vasogenic edema - the abnormal
permeability of the BBB - in comparison to DXM.
These administration routes are, overall, the most clinically accepted and effective means of
delivering drug to a localized site, especially in regard to the intraventricular and intracranial
methods.
4.4.2 Intranasal
A much less clinically proven method of delivering drugs to the CNS is through the nose so as to
access the olfactory neural pathway. Delivery through this pathway is mostly dependent upon
the drug's formulation (i.e. viscosity, pH, pharmaceutical form, pharmaceutical excipients),
physicochemical properties of the drug (i.e. MW, lipophilicity, pKa, stability, solubility), and
nasal physiological factors (i.e. blood flow, mucociliary clearance, enzymatic degradation,
transporters and efflux systems)65 . Intranasal administration is the least invasive, compared to
the previously discussed administration routes, because it is "essentially painless" and has a
"favorable tolerability profile"65. It provides a rapid means of delivery, yields a higher drug
concentration in CSF66, in comparison to systemic methods, and it also does not require the use
of carriers52. Disadvantages associated with the use of this method, include: "insufficient drug
absorption through the nasal mucosa," restriction of the administered drug formulation to about
100-200iL, due to the low volume of the nasal cavity6 5'66, enzymatic degradation of the drug
formulation as it travels through the olfactory epithelium 65, inhibition of hydrophilic drugs, like
DXM67, and although it bypasses the BBB, P-glycoprotein at the apical membrane surface
actively remove drugs from the CNS.
The delivery of corticosteroids using intranasal methods, despite the many challenges it poses,
has been recently studied and is still being pursued68. This administration method is also being
investigated as a means to deliver new drugs that treat brain tumors, which is also relevant to this
paper 5'69. A patent review of CNS drug delivery using intranasal administration was also
recently conducted 0 , which proves that this administration route is still being explored at both
the academic and industry level. Pires et al. argue the clinical prevalence and acceptance of
intranasal administration will be realized once more studies gather information regarding
"special characteristics of nasal mucosa, desirable physiochemical properties of drugs and
successful strategies to develop pharmaceutical formulations". The following references show
that there have, indeed, been many successful attempts in improving this administration
65,66,67
route
4.5 Device Design
4.5.1 Proposed Designs & General Considerations
A preliminary design of the device, as previously discussed, was based on the Ommaya
reservoir. There were three ways the original device could be modified in order to control drug
release and payload. The design on the left in Figure 11, is completely filled with solid drug -
both the reservoir and catheter - and relies upon diffusion through a specified number of orifices
at the distal end of the catheter. The center design is only filled with solid drug up to the
reservoir-catheter interface and relies upon the flow of CSF inside the orifices of the catheter,
where the CSF would then dissolve some of the solid drug before flowing back out into the
ventricular space. The design on the right is similar to the first, in terms of being completely
filled with drug, but it relies upon drug permeation through a semi-permeable membrane that
utilizes the entire surface area of the catheter.
Figure 10: Basic Illustrations of the Proposed, Preliminary Designs - Note: Not a technical drawing, and not
drawn to scale.
Associated with each design are important technical issues that need to be addressed. The
number and dimensions of the catheter holes will dictate the diffusion rate of drug, in regard to
the first and second designs. They also are more susceptible to failure due to biofouling, since
they can, for example, become occluded with tissue. The design of the third catheter will depend
upon the material chosen to allow DXM to permeate through it, and the use of a membrane has
also been suggested, in comparison to the first two designs, to prevent drug "dumping" or
resulting in an unintended overdose.
Members of Professor Cima's laboratory research group found through a series of experiments
that DXM in a solid dosage form is significantly more stable than in a liquid form. This
suggested that DXM could be implanted in vivo for > 4 months. A liquid formulation, however,
was advantageous in that it could be used to replenish the device with a transcutaneous injection
in an oupatient procedure. Therefore, rather than using a solid drug form that contained the
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payload needed for the entire treatment time, a liquid formulation can be administered on a
routine basis, which avoids concerns about long term stability.
To determine more detailed specifications of the device design, particularly its dimensions, data
pertaining to the drug release kinetics of DXM was needed. Qunya Ong, a graduate student in
Professor Cima's laboratory research group, investigated the in vitro permeability of DXM in a
liquid solution with an initial concentration of 500 mg/mL through a 20 mm silicone tube. The
tube was placed in a bath of artificial CSF (a-CSF) and had an inner and outer diameter of 0.305
mm and 0.635 mm, respectively. She found that the drug release kinetics of DXM was first-
order, and a plot of this data is shown in the figure below.
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Figure 11: Drug Release Profile for DXM Solution in Silicone Tube - Courtesy of Qunya Ong
The graph above depicts the cumulative release of DXM (in pig) from the inside of the silicone
tube to the a-CSF over a period of about 213 hours or 9 days. This drug release increases at a
decreasing rate, which suggests that it is exhibiting first order kinetics. The decreasing driving
force for diffusion explains the decreasing rate as the drug concentration in the a-CSF nears the
drug concentration inside the silicone tube.
The gathered permeability data was then used to determine whether the preliminary device
design was feasible. Assuming the rate-limiting step is permeation to the surrounding CSF or
tissue (i.e. convective fluid flow is unaccounted for) and steady-state diffusion, Fick's First Law,
shown below, was used to first calculate the permeability of DXM through silicone based on the
experiment performed by Qunya Ong.
J= - D (6c/6x),
where J = N/As, N is the rate of mass transport (jig/hour), As is the surface area over which
permeation occurs, D is the permeability constant, S4 is the concentration of drug at the solution-
tube interface compared to the CSF-tube interface, and 8x is the thickness of the silicone tube
through which DXM permeates. Using the calculated value of D and the required local drug
delivery rate needed to provide therapeutic effect (76.7 jg/hour), the length, inner diameter and
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outer diameter of the device were calculated. It was found that if the thickness, inner and outer
diameter were similar to the silicone tube used in Qunya Ong's experiment, then its length would
need to be greater than 6 cm, which is clinically unfavorable. Since the device was expected to
be implanted in the lateral ventricle, its dimensions must be constrained to the space available at
that site. A study done by Aitken found that the optimal length of a ventricular catheter should
extend no deeper than 6 cm, which is the distance between the scalp and the occipital horn of the
lateral ventricle". One way to increase the flux of drug that crosses the silicone membrane is by
reducing its thickness, and this is certainly possible with current fabrication techniques. There
are, however, two other concerns pertaining to this preliminary design that prompted the creation
of a different one. There is a risk that DXM may induce some level of toxicity to undesired parts
of the brain, considering the catheter extends into healthy brain tissue until it reaches the lateral
ventricle. Another concern that arose is that the device delivered drug at a constant rate as
opposed to the more clinically desirable, tapering dosage regimen.
At the time this paper was written, new design proposals were being investigated to help address
the concerns and limitations of the preliminary design proposal.
4.5.2 Implantation Considerations
A successful device design must account for the site in which it is implanted, the surgical
procedure required to successfully implant the device and its post-op use.
Two possible implantation sites, as previously mentioned, are intraventricular and intracranial
(intra-tumoral or peri-tumoral). Intracranial implantation of a drug delivery device is the most
direct in distributing therapeutic levels of drug uniformly. Several studies argue, however, that
uniform distribution of drug is also achieved through the intraventricular site, due to the
predictable flow of CSF8 7 ,72. The chosen implantation site will also depend on the site of the
tumor. For example, if a tumor is situated deep within healthy brain tissue, or in other words, is
deemed inoperable, then an intraventricular site would be more ideal. If the tumor site were near
the cerebral cortex (i.e. outer surfaces of the brain), then an intracranial site would be more
appropriate.
Intracranial implantation is more invasive and is associated with a greater risk of patient
morbidity (e.g. loss of neurological function), compared to intraventricular implantation. If the
device contains the drug payload for a minimum of four months, the implant will occupy a
volume that is dictated by the concentration of the drug formulation. Therefore, an intracranial
device will only be suitable for use after a tumor is removed, where a resection cavity is created.
A possible solution to this dilemma is to design a device that is more flexible, or in other words,
can be placed in either the intracranial or intraventricular site. A design primarily based on the
Ommaya reservoir could satisfy this demand. This is because most of the drug payload is held in
the subcutaneously implanted reservoir, and the catheter, which serves as a conduit, can vary in
length depending on where it is used. For example, a shorter catheter would be used for
intracranial delivery to a tumor in the cerebral cortex.
How the device will be fixated in its desired implantation site is another important consideration,
because the primary concern is device migration. For example, using free-floating, DXM-
impregnated microspheres would be unsuitable for intraventricular use, because there would be a
high risk of ventricular blockage of CSF flow.
For both intraventricular and intracranial implantation, there are a number of surgical procedures
that have been commonly used in clinical practice. Placement of shunts and ventricular
reservoirs are the most widely known intraventricular procedures. The details of these surgical
1673,74,7576
operations are discussed in: . Implantation basically involves the creation of a hole in
the skull a few millimeters in diameter (i.e. burr hole), which is typically placed in the frontal or
occipital-parietal region. A stylet is then used to guide a catheter to the anterior or posterior
horn, respectively, of the right or left lateral ventricle. Both ventricles are shown in the figure
below.
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Figure 12: Anterior and Left Lateral View of Brain's Ventricular System"
The insertion requires careful puncture of the
ventricle using a freehand technique or the use of
a stereotactic frame. In the presence of edema, a
neurosurgeon may cannulate the lateral ventricle
multiple times until proper penetration is
achieved. Misplacement of catheter tips into the
parenchyma's tissue has also been reported.
These surgical difficulties and risks can "increase
neurological morbidity and the need for additional
76th
operating time" . Fortunately, they have been
significantly minimized in recent years.
Intracranial implantation, in contrast, would most
likely involve a craniotomy, regardless if a patient
were contraindicated for surgical resection of their
tumor. Assuming the tumor is of a high grade or
large in size, which is more likely to cause the
formation of cerebral edema, the use of frame-
based stereotactic procedures is unnecessary, as
Figure 13: Stereotactic Frame for
Craniotomy, Brain Biopsy, Ventricular
Catheterization, etc.
shown in Figure 1378. It simply provides a more precise means of operating on small or low-
grade tumors. The surgical procedure for a craniotomy can be found in the following
references74'79 . It involves removing a flap of skin and skull to expose a desired area, where a
tumor can be removed and a drug delivery device left in its place. A simple illustration of a
craniotomy is shown in Figure 1480.
BCNU wafers are an example of a drug delivery device that has been discussed in this paper and
is commonly implanted after a tumor is resected. This proves that the idea of intracranial
implantation of drug delivery devices is accepted in a clinical setting, and would facilitate the
adoption of a new intracranial device. Despite the use of neuronavigational equipment and
microsurgical tools, intracranial implantation is Exmnple of a Craniotomy Procedure
highly invasive, requires 1-6 hours of operating time
(mostly due to the tumor's resection), and associated ""* """"
with a significantly increased likelihood of
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Another issue regarding surgical implantation is the
ease of its post-op use. If it is decided that a liquid
drug formulation be used, then the device should also (R i&8
be easily replenished with a minimally invasive
procedure, such as a transcutaneous injection to a
subcutaneously implanted reservoir.
The surgical implantation procedures of both types of
administration routes, in short, are commonly
performed in clinical settings. An intracranial device Figure 14: Basic Elements of a Craniotomy
would yield a higher incidence of patient morbidity, Procedure
but offer better drug distribution. An intraventricular
device, in contrast, is the least invasive, effective in delivering drug to both operable and
inoperable tumors, and easier to implant.
5 Conclusion & Future Work
Innovation is characterized by the successful merging of market, implementation and technology
aspects related to an idea. The merger can be achieved through a continuous cycle of iterations
that aim to improve each of the three aforementioned aspects. After each iteration, careful and
thoughtful analysis of each of these aspects helps to evaluate whether the idea deserves further
investment of time and money. This increases the effectiveness of available resources and
improves the efficiency of the innovation process.
In this paper, the novel design of a medical device intended to treat tumor-related cerebral edema
was evaluated based on an analysis of the technology, market and implementation aspects related
to the idea. Many valuable considerations were discussed and conclusions drawn, based on the
first iteration of the innovation cycle.
In the technical analysis, this paper identified and discussed what considerations are important in
the design of a successful drug delivery device, such as localized drug delivery so as to
. .............. .... .. .
circumvent the side effects of DXM and bypass many physiological barriers, such as the BBB,
Then, different methods of local drug delivery, including commercially available examples, were
identified and discussed. After evaluating the pros and cons of each type of administration route,
the one that offered the most benefits and the least limitations was the intraventricular route.
Finally, based on simple calculations, the preliminary design of the proposed device needed a
catheter that was longer than was clinically acceptable and could only provide a constant dosage
rate, and so this prompted the creation of a new design.
From the market analysis, the key members of the U.S. healthcare supply chain were first
discussed in terms of their importance in commercializing the novel device. The challenges
associated with entering the medical device industry were also discussed, because a small startup
will face the same ones as a large company. Thus, this highlights the importance for a startup to
collaborate with a well-entrenched competitor, as they can be instrumental in successfully
delivering the novel device to the market. In addition, the total market size for cerebral edema
treatment was determined to be as large as 200,000, which is expected to grow rapidly over the
next decade. It was further estimated that brain cancer patients spend anywhere between $403
and $960 per year for a four month treatment time, but it would cost an additional $565 to treat
some of the side effects of DXM. The cost of the new device was then estimated using a top-
down approach and the prices charged by a few of the device's competitors. Total cost was
calculated to be either $484 or $1,984, depending upon whether the device is implanted during
the tumor's resection. Even if the higher cost was charged, it provides an improved quality of
life, which is more important than the additional cost of the new device, in comparison to the
total cost of current treatment. Furthermore, the device's competitors were identified as being
the manufacturers of emerging drugs, treatments for treating the side effects of DXM, and
medical device manufacturers who make local drug delivery and ICP management devices that
could be modified to treat cerebral edema. Their charged prices were indicative of the maximum
limit the new device could be sold, such that health insurance companies can reimburse its price
and provide maximum profit. Finally, the profit margin of this device was estimated to be
between 5% and 20%, even though it could potentially be much greater than this.
From the implementation analysis, a strategy for obtaining FDA approval was discussed, where
an NDA under section 505(b)(2) was found to be the most desirable pathway to approval. This
is expected to reduce both the cost and time it takes for the device to reach the market. Based on
a preliminary design, a manufacturing process was suggested, where the components are first
derived from two different supply chains and then hand assembled, sterilized and packaged prior
to customer delivery. It was found that this takes advantage of pre-existing supply chains,
reduces total risk and capital costs needed to run the startup, and helps to integrate the startup
into the current supply chain infrastructure. Then, prior art and competing patents relevant to the
preliminary design were identified. A supply chain strategy, business model, and progress
timeline were outlined, where it is hoped that a device based on a pre-existing medical device
would facilitate its clinical adoption. A bottom-up approach was then used to determine the cost
of the product and its realizable profit, based on the capital investment needed to fund the
startup's operation ($8.14 million), which included R&D, manufacturing on a medium scale,
distribution, marketing, sales and other expenses. Finally, additional sources of funding to help
support the project's progress through its various stages of development and commercialization
were identified.
Although the device is still in its early stages of research and development, it seems very
promising, as demonstrated by this paper's comprehensive evaluation. Its progress thus far
suggests that it will soon be realized as a successful innovation and therefore, its development
genuinely deserves further investment.
Below are some suggestions for future work that could be explored in a future feasibility study.
They encompass all three aspects of innovation - market, implementation and technology.
5.1 Market
" A more complete and accurate cost of morbidity associated with DXM use should be
determined that includes only the most common side effects reported, the cost of
prophylaxis and non-pharmaceutical treatment. Then, this should be evaluated relative to
the cost the patient will pay for the new device.
" Determine more accurate number of patients diagnosed with primary and metastatic brain
cancer that require treatment for edema - perhaps from the number of cases where the
tumor is physically large and of a high grade.
* Determine how much and under what billing code(s) health insurance companies - both
private and public - will reimburse the patient for this device.
" Compare cost of novel device with, if possible, new drugs that can replace DXM and
more competitors than the ones presented in this paper.
" Evaluate the potential introduction of this product in both developed and developing
foreign markets.
5.2 Implementation
e Regarding the FDA application process, it should be determined with great certainty what
preclinical and clinical data will be needed to gain approval.
" Once the final device design is conceived, in light of the device's dimensions, determine
how the device will be manufactured and what parameters are relevant for creating a
more accurate cost model. The patent search should also be modified to include prior art
and even competing technology that is more relevant to the new design.
" More accurate estimates of the start-up costs should also be obtained, such as the cost for
pre-clinical testing (based on specific experiments needed) and distribution (based on
shipping and handling). Costs for packaging, sterilization and the device's components
should also be determined from their respective vendors, contractors and/or
partners/collaborators.
* Due to recent U.S. healthcare legislation, the government is requiring that health
insurance be mandatory by 2013 and aiding those who currently cannot afford health
insurance8 2 . As a result, this may alter the process and guidelines by which medical
expense reimbursement is assessed. Furthermore, in order to adequately fund this new
initiative, many taxes were levied at the time this paper was written, including a medical
device sales tax of approximately 2.3%. Therefore, one must consider how this will
influence the supply chain strategy, the business model, production & development costs,
etc.
5.3 Technology
* Account for convective flow, such as CSF in the case of intraventricular administration.
It could either limit or promote the flux of drug from the device, but it certainly will help
to identify which design type is most suitable.
* To improve the preliminary design, use a thinner membrane for the silicone tube, or
increase its surface area (e.g. create dimples or pores). This will help to increase the
permeability of DXM, and therefore allow the catheter to be shortened.
* Another possible way to improve the preliminary design is by replacing silicone with a
material that provides a greater permeability to DXM. In addition to the ideal device
characteristics that were previously discussed, the material should be non-resorbable or
non-biodegradable (i.e. no degradation or loss of material due to corrosion, dissolution or
leaching), so that the less stable, liquid drug formulation can be used to replenish the
device throughout its time in vivo. The material should also be capable of being
manufactured into complex shapes (e.g. tubes and domes) with micro- or nano-scale
surface modifications (e.g. pores and dimples, in order to increase surface area).
* In order to conduct preclinical tests, a prototype, scaled down for an animal model, must
be fabricated. It is also important to devise a lab-scale fabrication process so as to retain
consistent quality amongst all the tested devices.
" A quantitative, comparative analysis of the different types of administration routes and
the devices associated with them.
" Investigate other, less clinically common, routes of CNS drug delivery, particularly
intraocular and transdermal (e.g. iontophoresis).
" Obtain feedback from neurosurgeons and oncologists about the proposed design.
6 Appendix
6.1 Properties of Dexamethasone Sodium Phosphate
Molecular Weight = 516 g/mo1 83
Solubility in Water = 50 mg/mL 83
Inorganic, Hydrophilic Ester84
Average Particle Size = ~50-100 pm 85
Morphology: Irregular shaped crystalline particles8 5
Concentration in Solution (commercially available)= 4 mg/mL2 5
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